Hana Pharm (KOSDAQ 293480) stock outlook 2026: a Korean anesthetic-injectable maker with propofol and remifentanil leadership, narcotics-handling licensing as a real barrier to entry, hospital distribution, dividend cash flow, and drug-pricing and regulatory risk for foreign investors.
Samil Pharmaceutical (KOSPI 000520) 2026 stock outlook. A deep qualitative look at the Korean ophthalmic eye-drop franchise, the large sterile-ophthalmic CDMO plant in India, the operating leverage tied to plant utilization, the upfront capital burden, and what US investors should watch on tax and currency.
A 2026 outlook on Daewoong Co. (003090), the Korean HOLDING company that controls Daewoong Pharmaceutical. We cover NAV holding discount, Nabota and Fexuclue drug value, dividends and royalties, why 003090 is not 069620, key risks, and metrics to watch.
Samjin Pharmaceutical (KOSPI 005500) 2026 stock outlook. A deep look at the steady cash flow from its clopidogrel antithrombotic and Geworin OTC analgesic, the option value of the Magok R&D new-drug pipeline, and the drag from generic drug-pricing cuts and originator competition.
Bukwang Pharmaceutical (KOSPI 003000) 2026 stock analysis: steady generic and improved-drug cash flows, in-house antiviral Levovir (clevudine), the OCI Holdings ownership pivot and value-up angle, Contera Pharma's CNS movement-disorder pipeline, and the binary clinical risk investors must price.
Ildong Pharmaceutical (KRX: 249420) 2026 stock analysis: Aronamin and GQ-Lab OTC brand cash cows versus R&D losses at spun-off drug-discovery unit Yuhno-via, GLP-1 diabetes and obesity pipeline, licensing-out upside, Ildong Holdings structure, drug-pricing regulation risk, and balance-sheet improvement.
JW Pharmaceutical (KOSPI 001060) 2026 stock analysis: the high-barrier basic IV-fluid business, cash-cow prescription drugs like Livalo, a Wnt-targeting oncology pipeline, JW Holdings governance, drug-pricing regulation risk, and dividends — for investors accessing KOSPI directly.
Gilead Sciences (GILD) stock outlook 2026: Biktarvy $3.4B quarterly, Yeztugo $166M debut, anito-cel CAR-T PDUFA Dec 23, 2026, 2.46% dividend yield, analyst target $152. Full pipeline, risks, and 3 price scenarios for US investors.
AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.
AbbVie (ABBV) stock outlook 2026. Humira biosimilar erosion absorbed, Skyrizi+Rinvoq now exceeding peak Humira combined, 3.41% dividend yield, 12-month price target scenarios analyzed.